Processa Pharmaceuticals Inc PCSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCSA is a good fit for your portfolio.
News
-
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
-
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
-
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
-
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
-
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
-
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
-
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment
Trading Information
- Previous Close Price
- $2.43
- Day Range
- $2.02–2.35
- 52-Week Range
- $1.40–18.00
- Bid/Ask
- $2.04 / $2.14
- Market Cap
- $6.14 Mil
- Volume/Avg
- 1.9 Mil / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
Valuation
|
Metric
|
PCSA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.55 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PCSA
Financial Strength
|
Metric
|
PCSA
|
|---|---|
Quick Ratio | 6.44 |
Current Ratio | 7.71 |
Interest Coverage | — |
Quick Ratio
PCSA
Profitability
|
Metric
|
PCSA
|
|---|---|
Return on Assets (Normalized) | −111.76% |
Return on Equity (Normalized) | −129.22% |
Return on Invested Capital (Normalized) | −130.34% |
Return on Assets
PCSA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vxldkrjmw | Jld | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dwpnvpxfd | Cxmffkh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vcdmrfqlv | Nkvybcm | $97.8 Bil | |
MRNA
| Moderna Inc | Pdxkbhhsw | Nflfw | $41.3 Bil | |
ARGX
| argenx SE ADR | Xgdmmbx | Ystc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Czydmjt | Tvbnq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykjlvlj | Wlmkdrz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gmhsdbvc | Xyvrx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Brntmvbhmt | Bsjgrp | $12.5 Bil | |
INCY
| Incyte Corp | Stkzhwvj | Ydhdp | $11.6 Bil |